Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 10 of 10 results for nilotinib

  1. Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (TA426)

    Evidence-based recommendations on dasatinib (Sprycel), nilotinib (Tasigna) and imatinib (Glivec) for untreated chronic myeloid leukaemia in adults.

    Technology appraisal guidance
    Published
    21 December 2016
    View recommendations

    Sections for TA426

  2. Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (TA425)

    Evidence-based recommendations on dasatinib (Sprycel), nilotinib (Tasigna) and high-dose imatinib (Glivec) for treating imatinib-resistant or intolerant chronic myeloid leukaemia in adults.

    Technology appraisal guidance
    Published
    21 December 2016
    View recommendations

    Sections for TA425

  3. Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors (TA813)

    Evidence-based recommendations on asciminib (Scemblix) for chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors.

    Technology appraisal guidance
    Published
    3 August 2022
    View recommendations

    Sections for TA813

  4. Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia (TA451)

    Evidence-based recommendations on ponatinib (Iclusig) for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia in adults.

    Technology appraisal guidance
    Published
    28 June 2017
    View recommendations

    Sections for TA451

  5. Bosutinib for previously treated chronic myeloid leukaemia (TA401)

    Evidence-based recommendations on bosutinib (Bosulif) for previously reated chronic myeloid leukaemia in adults.

    Technology appraisal guidance
    Published
    24 August 2016
    View recommendations

    Sections for TA401

  6. Guidance on the use of imatinib for chronic myeloid leukaemia (TA70)

    Evidence-based recommendations on imatinib for people with chronic myeloid leukaemia.

    Technology appraisal guidance
    Last updated
    21 January 2016
    View recommendations

    Sections for TA70

  7. Nilotinib for the first line treatment of chronic myeloid leukaemia [ID79]

    Discontinued [GID-TAG408]

    Technology appraisal guidance
    Discontinued

  8. Past appeals and decisions

    rituximab 25 May 2010 TA251 Leukaemia (chronic myeloid) - dastatinib, nilotinib, imatinib (intolerant, resistant) (including partial...

  9. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia (TA251)

    This guidance has been updated and replaced by NICE technology appraisal guidance 426.

    Technology appraisal guidance
    Published
    25 April 2012

  10. Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML) (part review of NICE technology appraisal guidance 70), and dasatinib and nilotinib for people with CML for whom treatment with imatinib has failed because of intolerance (TA241)

    This guidance has been updated and replaced by NICE technology appraisal guidance 425.

    Technology appraisal guidance
    Published
    13 January 2012